Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
1 drugs in development
By Therapeutic Area
top 3
R&D Momentum
57/100
Pipeline Velocity
19/100
Trial Completion Rate
100/100
Pipeline Concentration
33/100
Pipeline Freshness
13/100
Strategic Signals
Activity
Last 14 days
Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Omega-3 Fatty Acid (O3FA) Supplementation for Adult and Juvenile Dermatomyositis (DM/JDM)
Reproductive Axis Maturation in the Early Post-Menarchal Years: A Pilot Study
The Role of the Functionally Relevant Single Nucleotide Polymorphisms CYP2J2 -50G>T (CYP2J2 7) and EPHX2 9846A>G (EPHX2 K55R) in Human Endothelial Function
Study of the Effect of Innate Immunity on the Inflammatory Response to Endotoxin
NIEHS EPA Pilot Study of Exposure to Chemicals in Consumer Products
Studies in the Natural History and Pathogenesis of Childhood-Onset and Adult-Onset Idiopathic Inflammatory Myopathies
Environmental Risk Factors for the Development of Myositis in Military Personnel
Personalized Environment and Genes Study
Cytochrome P450 Epoxygenase Pathway Regulation of Macrophage Function
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)